• Aliases: AZD6474, ZD6474
    • An orally bioavailable 4-anilinoquinazoline that selectively inhibits VEGFR2 and EGFR, as well as RET, protein tyrosine kinase 6 (BRK), TIE2, EPH, and SRC
    • FDA approved for MTC
    • First drug to be FDA approved for metastatic MTC in adult patients ineligible for surgery
    • Under investigation for other RET-mutated cancers such as NSCLC
    • Recommended dose: 300 mg PO once daily
    • Half-life: 19 days
    • Metabolism: Major CYP3A4 substrate
    • Common side effects: Contraindicated in patients with congenital long QT syndrome (US box warning), diarrhea, rash, acne, nausea, hypertension, decreased calcium, increased ALT, hypoglycemia
    Other topics in Targeted and Immunotherapy Agents